content.
Between August and October 2014, individuals with a physician's letter (in compliance with state laws) and no history of purchasing edible cannabis products were sent to the preselected dispensaries and instructed to buy as large a variety of products, in terms of type and labeled cannabinoid content, as possible within budget ($400/city). Purchasers, but not dispensary staff, were aware that the products would be evaluated following purchase. None knew the details of the analyses or testing to be completed.
Cannabidiol (CBD) and THC are typically the most concentrated chemical components of cannabis and are believed to primarily drive therapeutic benefit. 3 Studies suggest improved clinical benefit and fewer adverse effects with a THC: CBD ratio of 1:1. 4 Even though other cannabinoids were analyzed, results focus on THC and CBD. For testing, entire package contents were homogenized (crushed or mixed). Two 1.5-g (solid) or 25-g (liquid) samples of each product were tested via high-performance liquid chromatography, with results averaged and adjusted for total product weight.
When results of duplicate tests differed by more than 10% (cannabinoid heterogeneity), the entire product was analyzed (n = 37). Five randomly selected products in which duplicate testing was within 10% were subject to complete testing; results confirmed the accuracy of the duplicate testing method. Products were considered accurately labeled if the measured THC and CBD content was within 10% of the labeled values, underlabeled if the content was more than 10% above the labeled values, and overlabeled if the content was more than 10% below the labeled values.
A χ 2 test was used (SPSS version 22; SPSS Inc) to evaluate effects of location on label accuracy. Significance was determined at P < .05 (2-sided).
Results | Of 75 products purchased (47 different brands), 17% were accurately labeled, 23% were underlabeled, and 60% were overlabeled with respect to THC content ( Table 1 ). The greatest likelihood of obtaining underlabeled products was in Los Angeles and overlabeled products in Seattle (χ 2 = 12.94, P = .01).
Non-THC content was generally low ( Table 2) . Forty-four products (59%) had detectable levels of CBD; only 13 had CBD content labeled. Four products were underlabeled and 9 were overlabeled for CBD. The median THC:CBD ratio of products with detectable CBD was 36:1, 7 had ratios of less than 10:1, and only 1 had a 1:1 ratio.
Discussion | Edible cannabis products from 3 major metropolitan areas, though unregulated, failed to meet basic label accuracy standards for pharmaceuticals. Greater than 50% of products evaluated had significantly less cannabinoid content than labeled, with some products containing negligible amounts of THC. Such products may not produce the desired medical benefit.
Other products contained significantly more THC than labeled, placing patients at risk of experiencing adverse effects. 5, 6 Because medical cannabis is recommended for specific health conditions, regulation and quality assurance are needed.
A limited number of cities, dispensaries, and products were included. Because no source lists all dispensaries, and many products are not labeled with cannabinoid content, a true random sample was not possible and the results may not be generalizable. However, this study illustrates the variability in label accuracy for edible cannabis products within 2 of the largest medical cannabis markets in the United States. 
